Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Employees - 19, CEO - Mr. Ryan M. Confer M.S., Sector - Healthcare, Country - US, Market Cap - 10.43M

Altman ZScore(max is 10): -72.62, Piotroski Score(max is 10): 2, Working Capital: $-324791, Total Assets: $3907265, Retained Earnings: $-150468981, EBIT: -22825175, Total Liabilities: $2242294, Revenue: $23154

- Current Price $0.43 - Analyst Target Price $7.50